Key Takeaways
- Cathie Wood’s ARK Invest purchased 359,612 shares of Rocket Lab valued at $25.13 million on September 22 across three ETFs.
- Rocket Lab stock was trading around $70, representing a decline of approximately 53% from its 52-week peak of $151.
- The investment firm continued accumulating Scribe Therapeutics, purchasing 39,149 shares valued at over $1 million last Thursday.
- ARK reduced holdings in Alphabet, AMD, and Palantir while reallocating capital to Rocket Lab and similar positions.
- Rocket Lab currently holds a $2.36 billion backlog and is pursuing an $8 billion acquisition of Iridium.
Cathie Wood’s investment management firm, [[LINK_START_1]]ARK Invest[[LINK_END_1]], has been accumulating shares of both Rocket Lab and Scribe Therapeutics during recent market sessions. The firm’s trading activity demonstrates a clear strategy of building positions in underperforming equities while reducing exposure to established technology giants.
During trading on September 22, ARK acquired 359,612 shares of Rocket Lab, representing a total investment of $25.13 million.
The acquisition was distributed among three distinct ARK exchange-traded funds. The ARK Innovation ETF secured 277,573 shares. The ARK Autonomous Technology & Robotics ETF added 59,746 shares. The ARK Space Exploration ETF purchased 22,293 shares.
Rocket Lab Stock Experiences Significant Decline
Rocket Lab shares settled at $70.31 on September 23. This valuation represents approximately 53% below the stock’s previous peak of $151.
Multiple headwinds have impacted the stock’s performance. The aerospace company delayed the expected maiden flight of its Neutron rocket system. Additionally, management issued gross margin projections that fell short of analyst expectations.
The company is currently navigating an $8 billion transaction to acquire Iridium, a satellite communications provider. This pending acquisition introduces additional financing complexities and potential shareholder dilution concerns.
To secure funding for the acquisition, Rocket Lab arranged a $3.6 billion bridge financing facility. The company also completed an equity offering that raised approximately $2 billion.
ARK’s buying activity wasn’t limited to a single session. Earlier in September, the fund accumulated 705,102 shares of Rocket Lab worth $44.4 million during two separate trading days.
Back in July, ARK acquired 62,497 shares of Rocket Lab. During the same period, the fund divested 184,670 shares of Iridium, the very company Rocket Lab intends to purchase.
In its most recent quarter, Rocket Lab reported a 62% revenue increase to a record $234 million. The company’s order backlog now totals $2.36 billion. Its Electron launch vehicle successfully completed its 96th mission this month.
ARK Reduces Exposure to Established Tech Companies
ARK has been liquidating positions in several major technology corporations to finance alternative investments. On September 22, the firm divested $5.83 million in Alphabet shares.
In recent weeks, ARK has also scaled back its AMD and Palantir positions. The investment firm has been redirecting resources toward companies it perceives as more significantly undervalued.
Concurrently, ARK has maintained its accumulation of Scribe Therapeutics, a gene-editing biotechnology firm. On Thursday, September 24, the fund added 39,149 shares valued at $1,038,622 through its ARKG ETF.
This purchase came after more substantial acquisitions earlier in the same week. On Wednesday, ARK secured 143,257 shares of Scribe Therapeutics worth more than $4 million. The previous Tuesday saw the fund purchase 88,323 shares valued at nearly $2.5 million.
ARK also acquired Beam Therapeutics shares on Wednesday. The fund purchased 65,553 shares with an approximate value of $1.7 million.
Meanwhile, ARK liquidated approximately $7 million in Tempus AI stock on Wednesday. This divestment signaled a retreat from the artificial intelligence healthcare company.
In her most recent communication to investors, Wood stated that the present technology era is “likely to dwarf the Industrial Revolution.” She expressed ARK’s anticipation of substantial growth across artificial intelligence, robotics, energy storage, and genomics sectors.
Wood’s current trading patterns reveal sustained enthusiasm for gene-editing technologies and space industry investments, despite scaling back certain positions in more established technology companies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
